Clinical Trial Update: ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency [Phase 2]

View source ↗

Summary

This Phase 2 long-term safety study of INZ-701 in patients with ENPP1 deficiency and ABCC6-related disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arterial Calcification
• Autosomal Recessive Hypophosphatemic Rickets Type
• Ectonucleotide Pyrophosphatase Phosphodiesterase Deficiency
• Pseudoxanthoma Elasticum

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Status: RECRUITING